Optipharm.CO.LTD Cash Flow-to-Debt Ratio
Optipharm.CO.LTD cash flow-to-debt ratio. Optipharm.CO.LTD (153710) has a Cash Flow-to-Debt Ratio of 0.06x as of June 2026, meaning its operating cash flow of ₩905.29 Million could theoretically repay 0% of its total liabilities (₩15.42 Billion) in one year. Check Optipharm.CO.LTD (153710) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Optipharm.CO.LTD (2015–2025)
Cash flow-to-debt ratio of Optipharm.CO.LTD from 2015 to 2025. Historical debt coverage capacity for Optipharm.CO.LTD across 11 annual periods. Check 153710 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Optipharm.CO.LTD Cash Flow-to-Debt Ratio by Year (2015–2025)
Optipharm.CO.LTD cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Optipharm.CO.LTD. For the full cash flow conversion analysis, see 153710 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.10x | ₩-1.55 Billion | ₩15.37 Billion | ▼ -171.5% |
| 2024 | -0.04x | ₩-595.50 Million | ₩15.98 Billion | ▲ +69.4% |
| 2023 | -0.12x | ₩-1.72 Billion | ₩14.13 Billion | ▲ +39.0% |
| 2022 | -0.20x | ₩-2.43 Billion | ₩12.17 Billion | ▼ -3.7% |
| 2021 | -0.19x | ₩-1.97 Billion | ₩10.21 Billion | ▲ +10.0% |
| 2020 | -0.21x | ₩-1.62 Billion | ₩7.54 Billion | ▼ -392.7% |
| 2019 | 0.07x | ₩447.47 Million | ₩6.11 Billion | ▼ -56.2% |
| 2018 | 0.17x | ₩1.20 Billion | ₩7.20 Billion | ▲ +352.4% |
| 2017 | 0.04x | ₩260.86 Million | ₩7.06 Billion | ▼ -69.6% |
| 2016 | 0.12x | ₩861.36 Million | ₩7.08 Billion | ▲ +312.5% |
| 2015 | -0.06x | ₩-751.51 Million | ₩13.12 Billion | — |